ClinicalTrials.gg
CompletedNCT04311632Updated Feb 27, 2025Results posted

A Dose Escalation Study in de Novo Renal Transplantation

A Phase 2 interventional study of TCD601 and Tacrolimus (TAC) in Kidney Transplantation, sponsored by ITB-Med LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by ITB-Med LLC · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to understand the study requirements and provide written before and study assessment is performed.
  • Male or female patients ≥ 18 to 70 years of age.
  • Recipients of a de novo renal allograft from a heart-beating deceased, living unrelated, or non-HLA identical living related donor.
  • Recipients of a kidney with a cold ischemia time (CIT) less than 30 hours.

Key Exclusion Criteria:

  • Multiple-organ transplant recipients
  • Subjects who have received a kidney allograft previously
  • Recipient of a kidney from an HLA identical living related donor
  • Recipient of a kidney from a donor after cardiac death
  • Subjects at high immunological risk for rejection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Arm 1

    TCD601 administered with the standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)

  • Experimental
    Arm 2

    TCD601 administered with the standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)

  • Active comparator
    Arm 3

    ATG administered with the standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF) · Drug: ATG

Interventions

  • BiologicalTCD601

    Investigational Product

  • Standard of Care Concomitant Immunosuppression

  • DrugCorticosteroids (CS)

    Standard of Care Concomitant Immunosuppression

  • Standard of Care Concomitant Immunosuppression

  • DrugATG

    Standard of Care induction therapy in solid organ transplantation

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0.

    Time frame: 12 months

  2. Measure Peak Plasma Concentration (Cmax) Over Time.

    The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration.

    Time frame: 12 months

  3. Measure the Area Under the Plasma Concentration Versus Time Curve (AUC).

    The AUC from time zero to the last measurable concentration sampling time.

    Time frame: 12 months

Secondary outcomes

  1. The Incidence of Rejection at 12 Months Post-transplant.

    The incidence of treated biopsy-proven acute rejection (tBPAR) and antibody medication rejection (AMR) at 12 months post-transplant.

    Time frame: 12 months

  2. To Assess the Change in Renal Function Over Time.

    Estimated glomerular filtration rate (eGFR) was calculated using the MDRD4 equation. Mean+-SD eGFR values are presented at 3, 6, and 12. and compared against baseline (1 Month post-transplant).

    Time frame: 12 months

07

Results

Posted Feb 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm 1Arm 2Arm 3
Started247
Completed246
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0.
Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0.
ParticipantsArm 1Arm 2Arm 3
At least 1 TEAE — Yes247
At least 1 TEAE — No000
At least 1 TEAE Related to Study Medication — Yes234
At least 1 TEAE Related to Study Medication — No013
At least 1 SAE — Yes215
At least 1 SAE — No032
At least 1 TEAE leading to Study Discontinuation — Yes000
At least 1 TEAE leading to Study Discontinuation — No247
At least 1 TEAE leading to Dose Adjustment — Yes000
At least 1 TEAE leading to Dose Adjustment — No247
At least 1 TEAE leading to Dose Interruption — Yes001
At least 1 TEAE leading to Dose Interruption — No246
At least 1 TEAE leading to Study Medication Discontinuation — Yes000
At least 1 TEAE leading to Study Medication Discontinuation — No247
At least 1 Infection — Yes236
At least 1 Infection — No011
At least 1 Serious Infection — Yes101
At least 1 Serious Infection — No146
At least 1 SAE related to Study Medication — Yes100
At least 1 SAE related to Study Medication — No147
PrimaryMeasure Peak Plasma Concentration (Cmax) Over Time.

The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration.

Time frame:
12 months
Reported as:
Mean · ug/mL
Measure Peak Plasma Concentration (Cmax) Over Time.
ug/mLArm 1Arm 2
Measure Peak Plasma Concentration (Cmax) Over Time.5.0 ± 0.217.5 ± 1.1
PrimaryMeasure the Area Under the Plasma Concentration Versus Time Curve (AUC).

The AUC from time zero to the last measurable concentration sampling time.

Time frame:
12 months
Reported as:
Mean · ug/mL*day
Measure the Area Under the Plasma Concentration Versus Time Curve (AUC).
ug/mL*dayArm 1Arm 2
Measure the Area Under the Plasma Concentration Versus Time Curve (AUC).23.0 ± 0.5162.0 ± 53.4
SecondaryThe Incidence of Rejection at 12 Months Post-transplant.

The incidence of treated biopsy-proven acute rejection (tBPAR) and antibody medication rejection (AMR) at 12 months post-transplant.

Time frame:
12 months
Reported as:
Count of participants · Participants
The Incidence of Rejection at 12 Months Post-transplant.
ParticipantsArm 1Arm 2Arm 3
tBPAR — Yes101
tBPAR — No146
AMR — Yes000
AMR — No247
SecondaryTo Assess the Change in Renal Function Over Time.

Estimated glomerular filtration rate (eGFR) was calculated using the MDRD4 equation. Mean+-SD eGFR values are presented at 3, 6, and 12. and compared against baseline (1 Month post-transplant).

Time frame:
12 months
Reported as:
Mean · mL/minute/1.73m^2
To Assess the Change in Renal Function Over Time.
mL/minute/1.73m^2Arm 1Arm 2Arm 3
Baseline40.4 ± 5.050.2 ± 21.145.9 ± 5.8
Month 340.5 ± 0.348.2 ± 9.448.2 ± 10.0
Month 639.0 ± 5.651.4 ± 8.947.2 ± 17.0
Month 1244.0 ± 7.053.7 ± 14.146.0 ± 14.3

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 10/2 (0%)2/2 (100%)2/2 (100%)
Arm 20/4 (0%)1/4 (25%)4/4 (100%)
Arm 30/7 (0%)5/7 (71.4%)7/7 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventArm 1Arm 2Arm 3
Transplant rejectionImmune system disorders1/20/41/7
Urinary tract infectionInfections and infestations1/20/40/7
DehydrationMetabolism and nutrition disorders1/20/40/7
Deep vein thrombosisVascular disorders1/20/40/7
Cardiac failure chronicCardiac disorders0/21/40/7
DiarrhoeaGastrointestinal disorders0/20/41/7
PyrexiaGeneral disorders0/20/41/7
UrosepsisInfections and infestations0/20/41/7
Complications of transplanted kidneyInjury, poisoning and procedural complications0/20/41/7
Acute kidney injuryRenal and urinary disorders0/20/41/7
Most frequent other events
Showing 10 of 61
Most frequent other events
EventArm 1Arm 2Arm 3
DiarrhoeaGastrointestinal disorders1/21/42/7
NauseaGastrointestinal disorders0/22/40/7
FatigueGeneral disorders0/22/41/7
BK virus infectionInfections and infestations1/20/41/7
Cytomegalovirus infectionInfections and infestations1/22/41/7
Incision site painInjury, poisoning and procedural complications1/21/42/7
Alanine aminotransferase increasedInvestigations1/20/40/7
Aspartate aminotransferase increasedInvestigations1/20/41/7
Blood creatinine increasedInvestigations1/21/42/7
HypomagnesaemiaMetabolism and nutrition disorders1/20/42/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1Arm 2Arm 3Total
Mean29 ± 5.742 ± 10.851.3 ± 4.745 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1Arm 2Arm 3Total
Female1023
Male14510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1Arm 2Arm 3Total
Hispanic or Latino0011
Not Hispanic or Latino24612
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1Arm 2Arm 3Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0123
White23510
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Arm 1Arm 2Arm 3Total
United States24713
Height
Height(centimeters)Arm 1Arm 2Arm 3Total
Mean171.0 ± 16.9188.0 ± 4.4177.7 ± 8.9179.1 ± 10.4
Weight
Weight(kilograms)Arm 1Arm 2Arm 3Total
Mean66.8 ± 32.4115.5 ± 16.596.8 ± 19.797.9 ± 24.8
BMI
BMI(kg/m^2)Arm 1Arm 2Arm 3Total
Mean22.1 ± 6.630.5 ± 2.930.6 ± 4.629.0 ± 5.3

3 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Emory University
    Atlanta, Georgia 30322, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Oct 2023, 28 months.

Results were first posted in Feb 2025, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2020
First posted
Mar 17, 2020
StartActual
May 26, 2021
Primary completionActual
Oct 3, 2023
CompletionActual
Oct 3, 2023
Results first posted
Feb 27, 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04311632
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Mar 17, 2020
Start date
May 26, 2021
Primary completion
Oct 3, 2023
Completion
Oct 3, 2023
Results posted
Feb 27, 2025
Last update
Feb 27, 2025

Study contacts

Nick Hryciw, MA
study director · ITB-Med LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion